Published in Clin Infect Dis on July 15, 2009
The Respiratory Protection Effectiveness Clinical Trial (ResPECT) | NCT01249625
Investigate the Aerosol Particle Distribution During Aerosol Generating Procedures | NCT04353531
Influenza virus aerosols in human exhaled breath: particle size, culturability, and effect of surgical masks. PLoS Pathog (2013) 2.02
The effect of environmental parameters on the survival of airborne infectious agents. J R Soc Interface (2009) 1.90
A schlieren optical study of the human cough with and without wearing masks for aerosol infection control. J R Soc Interface (2009) 1.32
Airborne transmission of disease in hospitals. J R Soc Interface (2009) 1.20
Swine-origin H1N1 influenza A virus and dental practice: a critical review. Clin Oral Investig (2010) 0.94
Hajj pilgrims' knowledge about acute respiratory infections. Emerg Infect Dis (2009) 0.92
Qualitative real-time schlieren and shadowgraph imaging of human exhaled airflows: an aid to aerosol infection control. PLoS One (2011) 0.90
A quantitative assessment of the total inward leakage of NaCl aerosol representing submicron-size bioaerosol through N95 filtering facepiece respirators and surgical masks. J Occup Environ Hyg (2014) 0.86
Mycobacteria inactivation using Engineered Water Nanostructures (EWNS). Nanomedicine (2014) 0.85
Development and Performance Evaluation of an Exhaled-Breath Bioaerosol Collector for Influenza Virus. Aerosol Sci Technol (2013) 0.83
Exhaled air dispersion during coughing with and without wearing a surgical or N95 mask. PLoS One (2012) 0.81
Validation and application of models to predict facemask influenza contamination in healthcare settings. Risk Anal (2014) 0.80
Pro/con debate: are barrier precautions cost-effective in improving patient outcomes in the intensive care unit? Crit Care (2012) 0.76
Attitudes of influenza-vaccinated health care workers toward masks to prevent nosocomial transmission of influenza. Influenza Other Respir Viruses (2010) 0.76
Respiratory source control using a surgical mask: An in vitro study. J Occup Environ Hyg (2016) 0.75
Cluster randomised controlled trial to examine medical mask use as source control for people with respiratory illness. BMJ Open (2016) 0.75
Codetection of Respiratory Syncytial Virus in Habituated Wild Western Lowland Gorillas and Humans During a Respiratory Disease Outbreak. Ecohealth (2016) 0.75
A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol (2007) 5.12
Molecular epidemiology of human rotaviruses in Melbourne, Australia, from 1973 to 1979, as determined by electrophoresis of genome ribonucleic acid. J Clin Microbiol (1981) 4.23
Cryptosporidiosis in hospital patients with gastroenteritis. Am J Trop Med Hyg (1983) 2.45
The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis (2008) 2.39
Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS. J Infect Dis (1990) 2.02
Tuberculin-purified protein derivative-, MPT-64-, and ESAT-6-stimulated gamma interferon responses in medical students before and after Mycobacterium bovis BCG vaccination and in patients with tuberculosis. Clin Diagn Lab Immunol (1999) 1.97
Malaria acquired in Bali. Med J Aust (1995) 1.93
Direct detection of vanB2 using the Roche LightCycler vanA/B detection assay to indicate vancomycin-resistant enterococcal carriage--sensitive but not specific. J Antimicrob Chemother (2007) 1.88
Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS (2001) 1.82
Comparison of three PCR primer sets for identification of vanB gene carriage in feces and correlation with carriage of vancomycin-resistant enterococci: interference by vanB-containing anaerobic bacilli. Antimicrob Agents Chemother (2005) 1.81
Inactivation of feline calicivirus, a Norwalk virus surrogate. J Hosp Infect (1999) 1.81
Enterococcal vanB resistance locus in anaerobic bacteria in human faeces. Lancet (2001) 1.60
Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin Infect Dis (2013) 1.60
Antigenic analysis of rotavirus isolates using monoclonal antibodies specific for human serotypes 1, 2, 3 and 4, and SA11. J Gen Virol (1986) 1.59
Molecular characterization of vanB elements in naturally occurring gut anaerobes. Antimicrob Agents Chemother (2005) 1.58
Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother (2009) 1.50
A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia. Aust N Z J Med (2000) 1.42
HIV in the suburbs. Med J Aust (1993) 1.38
A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother (1996) 1.36
In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol (1995) 1.34
Association between severe pandemic 2009 influenza A (H1N1) virus infection and immunoglobulin G(2) subclass deficiency. Clin Infect Dis (2010) 1.32
Individuals from North America, Australasia, and Africa are infected with four different genotypes of human herpesvirus 8. Virology (1999) 1.32
High rates of fecal carriage of nonenterococcal vanB in both children and adults. Antimicrob Agents Chemother (2008) 1.29
Random amplified polymorphic DNA and plasmid analyses used in investigation of an outbreak of multiresistant Klebsiella pneumoniae. J Clin Microbiol (1995) 1.25
In vitro activity of sparfloxacin (AT-4140, CI-978, PD 131501), a new quinolone antimicrobial agent. Diagn Microbiol Infect Dis (1991) 1.19
Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. J Virol (1996) 1.18
Psittacosis--a review of 135 cases. Med J Aust (1988) 1.17
Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective. Eur J Clin Microbiol Infect Dis (2005) 1.16
Randomized clinical trial of enhanced recovery versus standard care after laparoscopic sleeve gastrectomy. Br J Surg (2013) 1.15
Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Med J Aust (2001) 1.15
Optimum treatment of staphylococcal infections. Drugs (1993) 1.13
Comparison of the Xpert methicillin-resistant Staphylococcus aureus (MRSA) assay, BD GeneOhm MRSA assay, and culture for detection of nasal and cutaneous groin colonization by MRSA. J Clin Microbiol (2009) 1.09
Human coronavirus OC43 causes influenza-like illness in residents and staff of aged-care facilities in Melbourne, Australia. Epidemiol Infect (2005) 1.09
Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization. Clin Microbiol Infect (2013) 1.09
Antimicrobial resistance testing of Helicobacter pylori: a comparison of Etest and disk diffusion methods. Pathology (1997) 1.09
Vancomycin vintage: my favourite DRESS. Intern Med J (2015) 1.08
Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci. Antimicrob Agents Chemother (1992) 1.07
It's time to move beyond trying to predict mortality using severity assessment tools in community-acquired pneumonia. Intern Med J (2014) 1.07
Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients. J Hepatol (1999) 1.05
Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS. J Med Virol (1995) 1.02
Antiviral strategies in chronic hepatitis B virus infection: I. Establishment of an in vitro system using the duck hepatitis B virus model. J Med Virol (1990) 1.01
Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1. Virology (1995) 1.01
Changing epidemiology of genital herpes simplex virus infection in Melbourne, Australia, between 1980 and 2003. Sex Transm Infect (2004) 1.01
Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy. J Infect Dis (1992) 1.00
The impact of the pandemic influenza A(H1N1) 2009 virus on seasonal influenza A viruses in the southern hemisphere, 2009. Euro Surveill (2010) 0.99
Improved detection of vanB2-containing enterococcus faecium with vancomycin susceptibility by Etest using oxgall supplementation. J Clin Microbiol (2008) 0.99
Stability of human immunodeficiency virus RNA in blood specimens as measured by a commercial PCR-based assay. J Clin Microbiol (1998) 0.99
Laboratory-supported influenza surveillance in Victorian sentinel general practices. Commun Dis Intell (2000) 0.97
Fecal colonization with vancomycin-resistant enterococci in Australia. Emerg Infect Dis (2000) 0.97
Assessing the risk of tuberculosis infection among healthcare workers: the Melbourne Mantoux Study. Melbourne Mantoux Study Group. Med J Aust (2001) 0.96
Radioimmunofocus assay for detection and quantitation of human rotavirus. J Clin Microbiol (1984) 0.96
Smoking and varicella pneumonia. J Infect (1988) 0.95
Home-based treatment of cellulitis with twice-daily cefazolin. Med J Aust (1998) 0.93
Severe dapsone syndrome due to weekly maloprim. Lancet (1988) 0.93
Clostridium lavalense sp. nov., a glycopeptide-resistant species isolated from human faeces. Int J Syst Evol Microbiol (2009) 0.93
The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis. J Antimicrob Chemother (1999) 0.93
Adenovirus eye infections in an Australian city, 1972-9. J Hyg (Lond) (1981) 0.92
Long-term foscarnet therapy not associated with the development of foscarnet-resistant human immunodeficiency virus type 1 in an acquired immunodeficiency syndrome patient. J Med Virol (1994) 0.92
Risk factors for adverse cutaneous reactions associated with intravenous vancomycin. J Antimicrob Chemother (1997) 0.91
A paired comparison of tuberculin skin test results in health care workers using 5 TU and 10 TU tuberculin. Thorax (2000) 0.90
Reversion from zidovudine resistance to sensitivity on cessation of treatment. Lancet (1991) 0.90
Hospital-in-the-home care: is it worth the hassle? Med J Aust (1998) 0.89
Cellular topoisomerase I activity associated with HIV-1. AIDS Res Hum Retroviruses (1993) 0.88
Polymicrobial septicaemia with Pseudomonas aeruginosa and Streptococcus pyogenes following traditional tattooing. J Infect (1997) 0.88
Evidence for late stage compartmentalization of HIV-1 resistance mutations between lymph node and peripheral blood mononuclear cells. AIDS (2000) 0.87
Electronic estimations of renal function are inaccurate in solid-organ transplant recipients and can result in significant underdosing of prophylactic valganciclovir. Antimicrob Agents Chemother (2013) 0.86
Use of a flavivirus RNA-dependent RNA polymerase assay to investigate the antiviral activity of selected compounds. Antiviral Res (1994) 0.85
Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy. HIV Clin Trials (2001) 0.84
Neurological complications of chlamydial infections: case report and review. Clin Infect Dis (1997) 0.83
Detection of varicella zoster virus in genital specimens using a multiplex polymerase chain reaction. Sex Transm Infect (2003) 0.83
Isoniazid toxicity in health care workers. Clin Infect Dis (1999) 0.83
Anchor placement and subsequent movement in a mesh kit with self-fixating tips: 6-month follow-up of a prospective cohort. BJOG (2014) 0.83
Compression sutures for uterine atony and hemorrhage following cesarean delivery. Int J Gynaecol Obstet (2005) 0.81
Significant reduction in vancomycin-resistant enterococcus colonization and bacteraemia after introduction of a bleach-based cleaning-disinfection programme. J Hosp Infect (2012) 0.81
Molecular characterization of a novel fastidious mycobacterium causing lepromatous lesions of the skin, subcutis, cornea, and conjunctiva of cats living in Victoria, Australia. J Clin Microbiol (2007) 0.81
The prevalence of fecal colonization with VRE among residents of long-term-care facilities in Melbourne, Australia. Infect Control Hosp Epidemiol (2001) 0.81
Inducible resistance to clindamycin in Staphylococcus aureus: validation of Vitek-2 against CLSI D-test. Pathology (2013) 0.81
Diarrheal disease in patients infected with human immunodeficiency virus in Bangkok, Thailand. Am J Trop Med Hyg (1999) 0.80
Can alcohol-based hand-rub solutions cause you to lose your driver's license? Comparative cutaneous absorption of various alcohols. Antimicrob Agents Chemother (2006) 0.79
[Infections in surgical departments of obstetrics and gynecology. Study of a 3-month period]. Ugeskr Laeger (1981) 0.79
Acceptability of early discharge, hospital at home schemes. Treatments that can be safely and acceptably managed at home need to be defined. BMJ (1998) 0.78
Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis (1997) 0.78
Safety of imipenem in neonates. Pediatr Infect Dis J (1995) 0.78
Sewage pollution of marine waters: the risks of viral infection. Med J Aust (1990) 0.78
Effect of anti-tuberculosis treatment on the tuberculin interferon-gamma response in tuberculin skin test (TST) positive health care workers and patients with tuberculosis. Int J Tuberc Lung Dis (2000) 0.78
Vibrio cholerae in Victoria. Med J Aust (2000) 0.77
Low rates of cutaneous adverse reactions to alcohol-based hand hygiene solution during prolonged use in a large teaching hospital. Antimicrob Agents Chemother (2005) 0.77
Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia. Clin Microbiol Infect (2012) 0.77
Cure of Rhizopus sinusitis in a liver transplant recipient with liposomal amphotericin B. Clin Infect Dis (1993) 0.77
Prolonged outbreak of Norwalk gastroenteritis in an isolated guest house. Med J Aust (1985) 0.76
Effects of halting a cervical screening programme. Lancet (1990) 0.76
Monoclonal gammopathy and septic arthritis. Aust N Z J Med (1999) 0.76
Pneumococcal arthritis and monoclonal gammopathy of undetermined significance. Aust N Z J Med (1997) 0.76
Physicochemical stability and inactivation of human and simian rotaviruses. Appl Environ Microbiol (1987) 0.76
Malaria acquired in Bali. Med J Aust (1995) 0.75
Still awaiting a useful tool for predicting severe CAP. Thorax (2006) 0.75
The difference between biological warfare and bioterrorism: Australia finally makes a start towards real preparedness for bioterrorism. Intern Med J (2003) 0.75
A potential "blind spot" in vancomycin treatment studies. Clin Infect Dis (2012) 0.75
Infection control practices. Med J Aust (1995) 0.75